Last reviewed · How we verify
NCT03887598
Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Breast Nodules
trial testing Ultrasound diagnosis in Breast Cancer in 2,000 participants. Status unknown.
18 January 2020
Quick facts
| Lead sponsor | Xin-Wu Cui |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 18 January 2019 |
| Primary completion | 18 January 2020 |
| Estimated completion | 18 February 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ultrasound diagnosis
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Xin-Wu Cui
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The application of computer-aided diagnosis (CAD) technology "S-Detect" enables qualitative and quantitative automated analysis of ultrasound images to obtain objective, repeatable and more accurate diagnostic results. The Elastic Contrast Index (ECI) technique, unlike conventional strain-elastic imaging techniques, can evaluate the elastic distribution in the region of interest. The purpose of the study was to evaluate the differential diagnosis value of ultrasound S-Detect technology for benign and malignant breast nodules and evaluate the differential diagnosis consistency of the ultrasound S-Detect technique and the examiner for benign and malignant breast nodules and explore the differential diagnosis value of Samsung ultrasound elastic contrast Index (ECI) technique for benign and malignant breast nodules.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations.
Hickman SE, Baxter GC, Gilbert FJ. · · 2021 · cited 65× · PMID 33772149 · DOI 10.1038/s41416-021-01333-w -
The diagnostic performance of ultrasound computer-aided diagnosis system for distinguishing breast masses: a prospective multicenter study.
Wei Q, Yan YJ, Wu GG, Ye XR, et al · · 2022 · cited 24× · PMID 35066633 · DOI 10.1007/s00330-021-08452-1
Verify or expand the search:
- PubMed search for NCT03887598
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ultrasound diagnosis
Trials testing the same drug.
- NCT03887611 — Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Thyroid Nodules · unknown
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Xin-Wu Cui trials
Trials by the same sponsor.
- NCT06468566 — Identification of Benign and Malignant Breast Nodules Using Ultrasound-modulated Optical Tomography: A Multicenter Study · recruiting
- NCT03887611 — Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Thyroid Nodules · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03887598 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xin-Wu Cui
- Last refreshed: 26 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03887598.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing